ABSTRACT
Background. Relapsing primary central nervous system lymphoma carries a poor prognosis when treated with conventional chemotherapy with a one-year overall survival of 25 % to 40 %. Encouraging results have been shown with intensive chemotherapy followed by autologous hematopoietic stem-cell rescue. We report the results of a large multicenter retrospective analysis of intensive chemotherapy followed by hematopoietic stem-cell rescue in immunocompetent adult patients with primary central nervous system lymphoma or intraocular lymphoma after the failure of high-dose methotrexate-based treatment.
Design and Methods.
Patients were included if they received intensive chemotherapy with a combination of thiotepa, busulfan, and cyclophosphamide.
Seventy-nine patients (median age, 52,4 years; range, 23 to 67 years) were identified. All of the patients except five received a salvage treatment after the failure of high-dose methotrexate. After salvage treatment and just before intensive chemotherapy followed by hematopoietic stem-cell rescue, 32 patients were in complete response, 26 patients were in partial response, 2 patients had stable disease and 19 patients had progressive disease.
Results.
With a median follow-up of 56 months, the 5-year overall survival probability was 51 % in the whole population and 62 % among patients who were chemosensitive to the salvage treatment. The 5-year event-free survival probability was 37.8 % in the whole population and 43.7 % in the chemosensitive subpopulation.
Neurocognitive assessments in a subset of patients suggest no evidence of intensive chemotherapy-induced neurocognitive decline.
Conclusion. Thiotepa, busulfan and cyclophosphamide-based intensive
chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years. The role of intensive chemotherapy followed by hematopoietic stem-cell rescue in chemorefractory patients needs to be defined more accurately.
INTRODUCTION
There is no consensus treatment for relapsed or primary refractory PCNSL.
Conventional second-line chemotherapies yield an overall response rate of approximately 30 % to 40 %, with short progression-free survival (PFS) leading to one-year overall survival (OS) of 25 % to 40 % 1 . Salvage radiotherapy, restricted to patients who had not received radiation as part of their first-line treatment, increases the median OS to approximately 11 months 2 . Plotkin et al. 3 reported, in a series of 22
selected patients who achieved CR with first-line HD MTX, a 62-month median overall survival from time of relapse when retreated with high-dose methotrexate at relapse. Patients obtained CR after a median of 6 cycles (range, 2-14) and were continued on treatment until relapse or death.
We previously reported the results of a prospective multicenter phase II study that evaluated the role of intensive chemotherapy followed by hematopoietic stem cell rescue for patients who failed to respond to first-line treatment including high-dose methotrexate 4 . Forty-three patients were included, and 27 received IC+ HCR. With a median follow-up of 36 months, the median OS of patients who were chemosensitive to salvage chemotherapy and who subsequently proceeded to the IC + HCR procedure was not reached. We also observed long survivors among patients who failed to respond to salvage chemotherapy but obtained complete remission after IC + HCR.
To better evaluate the results of IC + HCR in relapse or primary refractory PCNSL in a larger group of patients, we conducted a retrospective analysis in seven French centers.
DESIGN AND METHODS
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Adult immunocompetent patients with a PCNSL or an IOL were included in this study if they had failed high-dose methotrexate-based treatment and had undergone intensive chemotherapy with a combination of thiotepa (250 mg/m2/d on days 7 through 9), busulfan (total dose 10 mg/kg PO or 8 mg/kg IV on days 4 through 6,)
and cyclophosphamide (60 mg/kg/d on days 2 and 3), followed by hematopoietic stem cell rescue regardless of the disease status before intensification. The busulfan dose was reduced by 40% in patients 60 years of age and older. Patients from two previously published series were included 4, 5 . We defined the end points of OS, eventfree survival (EFS) and disease-free survival (DFS) according to the International Primary CNS Lymphoma Collaborative Group criteria 6 . Survival curves were plotted with the Kaplan-Meier method. The survival time was measured for all patients from the day of infusion of the stem cells to the last follow-up visit or death. EFS was measured for all patients from the day of infusion of the HCR to failure or death as a result of any cause. DFS was measured for patients in CR after IC + HCR from the day of infusion of the stem cells to the time of relapse. The statistical significance of intergroup differences was determined with the log-rank test, with a threshold of P = 0.05.
Relapse was defined as disease recurrence after CR lasting for at least one month since the cessation of therapy. Primary refractory disease was defined as stable disease (SD) or progressive disease (PD) during methotrexate-based first-line treatment or recurrence of the disease during therapy.
Relapse was qualified as chemosensitive if a PR or a CR was obtained after salvage treatment and as chemoresistant in the case of failure of the salvage chemotherapies.
Neuropsychological evaluations were performed in a subset of patients before and after intensification by neuropsychologists in a standardized manner. The All patients had signed an informed consent. This retrospective study has been approved by our institutional review board.
RESULTS
Patient characteristics
Seventy-nine patients (46 males and 33 females) were included (table 1) from 7
French centers. Their median age at time of intensification was 52,4 years (range, 23
to 67 years). Nineteen patients were older than 60 years, and 6 patients were 65 or older. Forty-seven patients were already part of two previously published series 4, 5 .
At the initial diagnosis, sixty-eight patients exhibited involvement of brain parenchyma. Eleven patients had isolated intraocular lymphoma with CSF infiltration 6 in two cases. Diffuse large B-cell lymphoma was the main histologic type (n= 68 cases). Other histologic subtypes were unclassified large cell (n= 6), immunoblastic (n= 2), plasmocytic differentiation (n=2) and T-cell (n= 1).
All of the patients had received high-dose methotrexate combined with either lomustine or procarbazine or with anthracycline, cyclophosphamide, vincristin, and prednisone, depending on the referring center. Eighteen patients received cranial irradiation as part of their first-line treatment, and 37 patients received additional intrathecal chemotherapy. Seven patients with primary refractory IOL did not receive salvage therapy. For the other 72 patients, the salvage treatment consisted mainly of high-dose Ara-C associated with VP16 (n = 55), cisplatin (n = 12) or methotrexate (n = 4). One patient received ifosfamide. Rituxan was associated with salvage treatment in 13 patients.
Intrathecal chemotherapy was added in 4 patients, and intraocular injection of methotrexate was utilized in 2 patients.
Intensive chemotherapy consisted of thiotepa, busulfan and cyclophosphamide, as described in methods
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. The busulfan dose was reduced by 40% in patients 60 years of age and older. Clonazepam (2 mg/d IV) was used to prevent seizures from the first day of busulfan therapy to the day after completion of busulfan therapy.
Hematopoietic stem cells were reinfused on day 0. Three patients did not receive 7 cyclophosphamide because of age (n = 1) or sepsis during intensive chemotherapy (n = 2).
IC + HCR was performed between December 1993 and March 2011.
After salvage treatment, just before intensification, 32 patients were in CR, 26 patients were in PR, 2 patients had stable disease and 19 patients had progressive disease.
Five patients received cranial irradiation after intensification. Three were in PD before IC+HCR. Two of them entered CR after intensification but before cranial irradiation;
the third patient was still in PD after IC + HCR. Two patients were in PR before IC+HCR. One of those patients was in CR after intensification and before cranial irradiation; the second was still in PR after IC+HCR and achieved CR after irradiation. Two patients received ocular radiation because of the failure of IC+HCR, which led to CR in one patient.
Response after IC + HCR
The best responses observed after intensification were CR in 66 patients and PR in 4 patients. Two and 3 patients had stable and progressive disease, respectively. The disease status was not evaluable in 4 patients who died soon after IC+HCR. Twentyeight patients subsequently relapsed with a median time of 18 months (range, 2.4-144) after IC+HCR.
Survival
Five patients were lost to follow-up 13, 52, 54, 56 and 64 months after IC + HCR.
With a median follow-up of 56 months among survivors, 35 patients remained alive.
Forty-four patients died. The causes of death were progression of the CNS lymphoma (n = 21); systemic relapse of the lymphoma (n = 2); CNS toxicity (n = 7); 8 pulmonary infection (n=1); other cancer (n = 2); treatment-related toxicity after IC + HCR (n = 6); and unknown causes (n = 5). and one is in CR with ongoing treatment), and three patients were alive with progressive CNS lymphoma.
Toxicity of the procedure
Six patients died after IC+HCR. Four of them, including one with progressive disease before IC+HCR, died before their lymphoma status could be evaluated, as a result of acute respiratory distress syndrome (n = 1); multiorgan failure (n = 1); pulmonary embolism (n = 1); and sepsis (n = 1). Two other patients died within 3 months after IC+HCR as a result of sepsis (n = 1) and hemorrhage (n=1).
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Grade 3 or 4 noninfectious complications were reported in 4 cases and involved severe veno-occlusive disease with a favorable outcome (n = 1); pancreatitis with a favorable outcome (n = 1); reversible acute renal insufficiency (n = 1); and reversible hemorrhagic cystitis (n = 1).
Neurocognitive outcome
Seven patients died as a result of severe CNS toxicity. Four patients had previously received cranial irradiation, and three had not.
Longitudinal neuropsychological assessments have been performed in ten patients with a neuropsychological assessment before IC + HCR and at least one assessments after IC +HCR. Before IC+HCR, 2 patients had no impairment, 3 had a mild impairment (2 with active disease, and one in CR), 3 patients had a moderate impairment and 2 had a severe impairment. These last 5 patients had active disease at time of cognitive assessment. After IC+HCR, cognitive performances improved from mild to normal (n=1), from severe to normal (n=1), and from moderate to mild (n=2). All these patients also improved their disease status entering CR after IC+HCR. Two patients showed worsening profile from mild to moderate. One of these patients had a relapse after IC+HCR and received additional irradiation, the other one was in prolonged CR and did not receive irradiation. Cognitive performances remained unchanged in 4 patients.
Nine patients had no pre IC+HCR assessment but completed at least 2 neuropsychological assessments after IC+HCR with a mean of 6 months interval.
Cognitive profile improved in 3 patients from moderate to normal (n=1), from severe to moderate (n=1), and from moderate to mild (n=1). Four patients remained stable with no cognitive change. Two patients showed worse cognitive performances at the second assessment (from mild to moderate and from moderate to severe). These two patients had a relapse after IC+HCR.
Neurocognitive assessments were repeated after IC + HCR in 13 patients every 6 months for the first 18 months and then at intervals of one year. Patients were followed up to 95 months after IC + HCR, with a median of 24 months (range, 6-95).
Prognostic factors
In the univariate analysis, age, chemosensitivity to the salvage treatment, achievement of a CR after IC+ HCR, and the combination of status before and after IC+HCR strongly influenced both OS and EFS. Age and chemosensitivity to the salvage treatment also influenced DFS (Table 2) .
Patients who were chemosensitive to the salvage treatment, thus achieving CR or PR before IC+HCR, had significantly better OS and EFS rates than those who had no objective response after salvage treatment. The respective probability of 5-year 
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OS was worse in patients over 60 than in younger patients. In multivariate analysis, OS was independently affected by age and by the combination of the chemosensitivity status to salvage treatment and response to IC+HCR (table S1, Supplemental data).
Outcomes for patients who experienced chemoresistant relapse
At the time of IC + HCR, eighteen patients had progressive disease, including isolated IOL (n = 5) and CNS lymphoma (n = 13). The five IOL patients were refractory to the first-line treatment and did not receive salvage treatment before IC+HCR. Four patients achieved CR after IC+HCR, and one patient continued to experience PD. He received ocular radiotherapy and died at 71 months after IC +HCR from unknown causes. His disease status after radiotherapy is unknown.
Three patients relapsed at 3, 36 and 145 months after IC+HCR. Among relapsing patients, one is alive on therapy at 68 months, and two patients died as a result of lymphoma at 149 months (n=1) and other cancer at 33 months (n=1), respectively.
One patient died 22 months after IC+HCR of unknown causes.
Among the thirteen patients with a chemoresistant CNS lymphoma at the time of IC+HCR, five patients were also refractory to first-line treatment. Ten patients entered CR after IC+HCR. Six patients subsequently relapsed at 3, 5, 6, 7, 11 and 52 12 months. Six patients experienced longer CR duration after IC+HCR than that achieved with prior therapies. Eleven patients died as a result of CNS lymphoma (n = 7), CNS toxicity (n = 1), pulmonary infection (n = 2), and unknown causes (n = 1).
Two patients were alive in CR at the last follow-up at 45 and 56 months (Table S2, Supplemental data).
DISCUSSION
The aim of this study was to validate the results we had previously obtained with IC + HCR for relapse or primary refractory PCNSL patients in a larger series. Seventynine patients were included in this retrospective analysis. All of the patients received the same intensive chemotherapy regimen consisting of thiotepa, busulfan and cyclophosphamide. The rationale for using this combination is discussed extensively in our pilot study 4 . Hematological toxicity was reported in our previous prospective phase II study 5 and was not evaluated in this series. Though retrospective, this series is the largest reported series of IC + HCR performed with homogeneous IC for relapse or primary refractory PCNSL that allowed for reliable evaluation of therapeutic results. However, incomplete data preclude the evaluation of potential prognostic factors such as performance status and LDH levels. Neurocognitive assessments performed in a subset of patients suggest no evidence of intensive chemotherapy-induced neurocognitive decline. To our knowledge, no such neurocognitive assessment has been performed after salvage radiotherapy, thus precluding from any comparison. The results of relapse or primary refractory IC+HCR in PCNSL reproduce those of systemic NHL obtained in the same setting 7, 8 . In systemic NHL, the conditioning regimen usually combines carmustine, etoposide, cytarabine, and melphalan (BEAM regimen). A meta-analysis of IC+HCR in PCNSL showed a trend toward better therapeutic results when the IC was based on thiotepa plus carmustine or busulfan 9 . Our results would need to be compared with a series of PCNSL patients who received the BEAM regimen to define the role of the association of thiotepa, busulfan and cyclophosphamide in PCNSL. Our series included patients who relapsed after first-line treatment as well as primary refractory patients, which differs from other published series that report the results of salvage treatment in nonHodgkin's lymphomas.
A few patients in PD after salvage treatment obtained long-lasting CR after IC+HCR.
Although the therapeutic results in this subpopulation are significantly worse than those of chemosensitive patients, 14 of out 18 patients entered CR after IC + HCR.
However, nine of them subsequently relapsed. These observations raise two issues.
First, the quality of a CR measured by magnetic resonance imaging might not be optimal, and secondly, maintenance treatment for these patients should be discussed. We cannot draw conclusions about the role of radiotherapy administered after IC + HCR in patients who were in PD before IC + HCR or who remained in PR after IC+HCR because of the small number of such patients.
CONCLUSION
In conclusion, this large retrospective series shows that IC based on thiotepa, busulfan and cyclophosphamide offers a real second chance for relapse or refractory PCNSL patients when chemosensitive to salvage treatment. IC + HCR in relapse or primary refractory PCNSL reproduced the results obtained in systemic NHL. This treatment is feasible in patients up to 60 years old but can also be tolerated in fit patients up to 65 years old, with reduced dose of busulfan.
As expected, patients who proved chemoresistant to the salvage treatment have a worse outcome. Long-term survivors are observed in this population, though no firm conclusions can be drawn. These patients should be considered for early-phase trials ). ‡Median, 13.5 months (2-154). Three patients in second relapse. 
